NASDAQ:MNPR

Monopar Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy MNPR

*Your capital is at risk

$60.56

-0.700 (-1.14%)

At Close: Jun 03, 2026

Monopar Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -84.86. In total, the insiders bought 847.34K and sold 1.42M MNPR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-84.86
● Buy	847.34K shares
● Sell	1.42M shares
63% Buy Activity Strong Negative Correlation
Sell Signal High Confidence Sep 24, 2025 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -84.86. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 31, 2026 Sell	Common Stock F-InKind	Cittadine Andrew Chief Operating Officer	C-Suite Officer	1 571 Value: $86.1K
Mar 31, 2026 Sell	Common Stock F-InKind	Robinson Chandler Chief Executive Officer	CEO / President	1 972 Value: $108.0K
Mar 31, 2026 Buy	Restricted Stock Unit M-Exempt	Robinson Chandler Chief Executive Officer	CEO / President	6 732 Value: $368.8K
Mar 31, 2026 Buy	Common Stock M-Exempt	Robinson Chandler Chief Executive Officer	CEO / President	6 732 Value: $368.8K
Mar 31, 2026 Buy	Common Stock M-Exempt	Cittadine Andrew Chief Operating Officer	C-Suite Officer	3 514 Value: $192.5K
Mar 31, 2026 Buy	Restricted Stock Unit M-Exempt	Cittadine Andrew Chief Operating Officer	C-Suite Officer	3 514 Value: $192.5K
Mar 02, 2026 Buy	Stock Options A-Award	Rodriguez Susan Ccso	Officer	48 728 Value: $2.61M
Mar 02, 2026 Buy	Common Stock J-Other	Rodriguez Susan Officer	Officer	0 Value: $0
Jan 01, 2026 Buy	Stock Option A-Award	Rioux Patrice Acting Chief Medical Officer	Officer	2 000 Value: $130.6K
Dec 31, 2025 Sell	Common Stock F-InKind	Cittadine Andrew Chief Operating Officer	C-Suite Officer	1 889 Value: $123.4K
Dec 31, 2025 Buy	Common Stock M-Exempt	Cittadine Andrew Chief Operating Officer	C-Suite Officer	4 326 Value: $282.5K
Dec 31, 2025 Buy	Common Stock M-Exempt	Robinson Chandler Chief Executive Officer	CEO / President	8 724 Value: $569.7K
Dec 31, 2025 Buy	Restricted Stock Unit M-Exempt	Robinson Chandler Chief Executive Officer	CEO / President	8 724 Value: $569.7K
Dec 31, 2025 Sell	Common Stock F-InKind	Robinson Chandler Chief Executive Officer	CEO / President	2 558 Value: $167.0K
Dec 31, 2025 Buy	Restricted Stock Unit M-Exempt	Cittadine Andrew Chief Operating Officer	C-Suite Officer	4 326 Value: $282.5K
Dec 26, 2025 Buy	Common Stock P-Purchase	Vu Quan Anh Chief Financial Officer	C-Suite Officer	1 500 Value: $104.9K
Dec 18, 2025 Sell	Common Stock S-Sale	Klausner Arthur J Director	Director	461 Value: $31.4K
Dec 18, 2025 Sell	Common Stock S-Sale	Klausner Arthur J Director	Director	4 660 Value: $312.5K
Dec 16, 2025 Buy	Common Stock J-Other	Klausner Arthur J Director	Director	7 710 Value: $551.0K
Dec 16, 2025 Sell	Common Stock J-Other	Hendricks Diane 10 Percent Owner	10% Owner	43 499 Value: $0
Dec 02, 2025 Buy	Stock Options A-Award	Robinson Chandler Chief Executive Officer	CEO / President	16 753 Value: $1.27M
Dec 02, 2025 Buy	Stock Options A-Award	Vu Quan Anh Chief Financial Officer	C-Suite Officer	7 135 Value: $541.8K
Dec 02, 2025 Buy	Stock Options A-Award	Tsuchimoto Kim R Director	Director	2 924 Value: $222.0K
Dec 02, 2025 Buy	Stock Options A-Award	Talukdar Lavina Director	Director	2 924 Value: $222.0K
Dec 02, 2025 Buy	Stock Options A-Award	Klausner Arthur J Director	Director	2 924 Value: $222.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MONOPAR THERAPEUTICS INC.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubic...

Read Full Profile Here